10x Genomics (TXG) CEO exercises options and updates shareholdings

Rhea-AI Filing Summary

10x Genomics, Inc. reported that Chief Executive Officer and director Serge Saxonov exercised stock options on January 5, 2026 to acquire 50,000 shares of Class A common stock at $1.20 per share. These shares now form part of his directly held stake of 1,071,556 Class A shares following the transaction.

The filing shows two option exercises, covering 17,463 and 32,537 underlying shares, from fully vested options expiring on October 18, 2027, leaving 173,600 stock options outstanding. In addition to his direct holdings, Saxonov is reported as trustee for three trusts that hold 27, 213,250 and 58,000 Class A shares, respectively.

Insider Trade Summary

50,000 shares exercised/converted

Mixed 6 txns

Insider Saxonov Serge

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	17,463	$0.00	--
Exercise	Stock Option (right to buy)	32,537	$0.00	--
Exercise	Class A Common Stock	50,000	$1.20	$60K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Class A Common Stock — 1,071,556 shares (Direct); Class A Common Stock — 27 shares (Indirect, See footnote)

Footnotes (1)

1. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/05/2026		M		50,000	A	$1.2	1,071,556	D
Class A Common Stock								27	I	See footnote(1)
Class A Common Stock								213,250	I	See footnote(2)
Class A Common Stock								58,000	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	01/05/2026		M			17,463	(4)	10/18/2027	Class A Common Stock	17,463	$0	0	D
Stock Option (right to buy)	$1.2	01/05/2026		M			32,537	(4)	10/18/2027	Class A Common Stock	32,537	$0	173,600	D

Explanation of Responses:

1. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

2. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

3. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

4. All of the shares subject to the option are fully vested and exercisable as of the date hereof.

	/s/ Serge Saxonov	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 10x Genomics (TXG) report for Serge Saxonov?

The company reported that Chief Executive Officer and director Serge Saxonov exercised stock options on January 5, 2026 to acquire 50,000 shares of Class A common stock at $1.20 per share.

How many 10x Genomics Class A shares does Serge Saxonov hold directly after this Form 4?

After the reported option exercise, Serge Saxonov directly holds 1,071,556 shares of 10x Genomics Class A common stock.

What option positions are disclosed for Serge Saxonov in this 10x Genomics Form 4?

The filing shows two exercised stock options covering 17,463 and 32,537 underlying Class A shares, with an exercise price of $1.20 per share and an expiration date of October 18, 2027. Following these exercises, 173,600 stock options remain outstanding.

Are any of Serge Saxonov’s 10x Genomics shares held through trusts?

Yes. The filing states that 27 Class A shares are held by the Andromeda Trust, 213,250 shares are held by the Y/S Descendants' Trust, and 58,000 shares are held by the Y/S Pot Trust, for which Serge Saxonov serves as trustee.

What does transaction code "M" mean in the 10x Genomics Form 4?

Transaction code "M" in the Form 4 indicates an exercise of a derivative security, in this case stock options, resulting in the acquisition of underlying Class A common shares.

What roles does Serge Saxonov hold at 10x Genomics according to this filing?

Serge Saxonov is reported as both a Director and an Officer of 10x Genomics, serving as the company’s Chief Executive Officer.